Lisanti Capital Dumps $5.4 Million Alphatec Stake as Medical Device Maker Struggles

Lisanti Capital Growth fully exited Alphatec, selling 372,407 shares in an estimated $5.42 million transaction and reducing the position to zero from 1.86% of AUM last quarter. The quarter-end value fell $7.84 million, reflecting both the sale and a decline in share price. The move underscores negative investor positioning toward Alphatec after its Q1 earnings miss and lowered full-year revenue guidance.

Analysis

A full exit by a growth-oriented small-cap manager matters less as a headline than as a signal that the market is now punishing narratives with any visible execution asymmetry. For ATEC, the key issue is not whether procedure volumes are improving, but whether the company can convert that adoption into durable gross margin and cash flow while one high-capex subsegment remains under pressure. In this setup, even incremental misses tend to have outsized multiple compression because the stock is already priced for a cleaner operating inflection than the company can currently demonstrate.

The second-order effect is competitive: capital and surgeon mindshare likely migrates toward peers that can bundle procedure growth with a more credible profitability path. That creates a feedback loop where weaker pricing power and slower rep conversion can show up in future quarters, especially if hospitals continue to scrutinize ROI on capital equipment and imaging workflows. For the broader medtech basket, this is a reminder that “growth” names with mixed product mixes can de-rate faster than the market expects once guidance credibility slips.

The selloff may also be reaching a zone where the bear case is becoming self-financing. At these levels, any stabilization in the underperforming division or a modest guide reset with no further downside surprise could force short covering over a 4-8 week horizon. The contrarian read is that the market may already be discounting a prolonged slowdown, so the next incremental catalyst is not top-line acceleration but evidence that management can defend margin and free cash flow despite slower capital sales.

Key Decisions for Investors

• Avoid initiating fresh longs in ATEC until the next print confirms whether EOS weakness is isolated or structural; risk/reward remains poor while the multiple is still anchored to execution recovery that has not yet been proven.
• For opportunistic traders, consider a tactical ATEC short on any post-earnings bounce that fails to reclaim prior breakdown levels; target a 4-8 week horizon with tight risk above the latest lower high because the stock remains vulnerable to another guidance reset.
• Relative-value idea: pair long better-executing medtech/healthcare names against ATEC on a basket basis, with the thesis that capital will rotate toward companies showing cleaner margin conversion and less mixed product exposure.
• If holding ATEC is unavoidable, prefer call spreads rather than stock for a speculative rebound; structure only after evidence of stabilization in the next quarter, since upside is likely to be capped by credibility concerns while downside remains open on any miss.